Innophore cavitomix: catalophore point-cloud technology and binding-site analysis for various industrial applications
Overview
CavitOmiX is Innophore’s platform for binding-site comparison and cavity analysis across biotechnology, pharmaceutical research, and life sciences. Its core technology uses Catalophore™ point clouds to describe protein pockets through 3D shape and physicochemical characteristics.
Rather than relying on sequence alignment or overall protein fold, CavitOmiX compares local pocket environments to identify related active sites and cavities across protein families.
The platform supports enzyme search, enzyme engineering, and strain optimization, as well as off-target search, side-effect prediction, and drug-discovery research. It helps identify alternative targets and enzymes, evaluate molecular interactions and selectivity, discover ligand-binding opportunities, transfer functional insights between biological systems, and improve enzyme function and microbial production systems.
Technical Specifications
CavitOmiX combines Catalophore™ point-cloud technology with AI-powered matching and structural data.
- Catalophore™ point clouds: Pockets are modelled as point clouds capturing spatial shape and local chemistry.
- Binding-site analysis: Local geometry is assessed independently of global sequence identity and protein fold.
- Physicochemical mapping: Captures electrostatics, hydrophobicity, accessibility, hydrogen bonding, and elasticity.
- Enzyme search: Identifies related catalytic pockets across protein families and sequence spaces.
- Enzyme engineering: Helps identify templates and active-site positions for modifying activity, selectivity, substrate scope, or stability.
- Strain optimization: Supports enzyme selection and pathway analysis for microbial production systems.
- Off-target search: Compares binding-site environments to identify potentially related protein cavities.
- Drug-discovery research: Supports target analysis and ligand-binding research.
TRL and Validation
CavitOmiX is an active computational platform developed by Innophore. Its Catalophore™ point-cloud technology is patented and supported by peer-reviewed studies in biocatalysis and protein biochemistry.
The platform produces prioritised computational hypotheses. Results, including potential off-target relationships and side-effect mechanisms, should be confirmed through biochemical, biophysical, cellular, or fermentation-based assays.
Partnership Opportunities
- Industrial biotechnology: Search for catalytic pockets, substrate-binding sites, and enzyme families.
- Protein engineering: Support structure-guided enzyme optimisation.
- Strain optimization: Support enzyme selection and pathway improvement.
- Pharmaceutical research: Support off-target search, side-effect prediction, target analysis, and drug-discovery research.
- Structural biology: Analyse and visualise pocket geometry and cavity networks.
More information is available on the CavitOmiX product page and Innophore’s technology overview.
About Innophore GmbH
Innophore GmbH is a biotechnology company that provides a platform for enzyme and drug discovery through its proprietary Catalophore technology. Founded in 2017 in Graz, Austria, the company uses artificial intelligence and 3D point-cloud analysis to characterize protein binding sites rather than focusing on proteins alone. This methodology allows the company to conduct cavity-based searches across entire proteomes, offering capabilities that exceed traditional sequence or fold comparison methods. By transforming molecular structure into actionable data, Innophore supports research and development pipelines by identifying and optimizing protein candidates for applications in biotechnology, pharmaceuticals, and industrial processes.
The company's technology is utilized by global partners in sectors including healthcare, chemicals, and consumer products to accelerate R&D and improve safety. Innophore’s solutions enable clients to detect potential off-target interactions, reduce side effects, and optimize therapeutic or industrial enzymes more efficiently. The company gained significant industry recognition during the COVID-19 pandemic by rapidly identifying the SARS-CoV-2 main protease as a drug target. Innophore maintains collaborations with major technology partners, such as NVIDIA, to leverage advanced computational platforms like BioNeMo for large-scale structural modeling and drug discovery predictions, helping clients bring products to market with greater speed and precision.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.